🔗 Visit the ClinicalTrials.gov page for NCT02484404
Rank | Title | Journal | Year | PubWeight™‹?› |
---|---|---|---|---|
1 | PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. | Int J Clin Oncol | 2016 | 0.95 |
2 | Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? | Int J Mol Sci | 2016 | 0.90 |
3 | The role of immune checkpoint inhibition in the treatment of ovarian cancer. | Gynecol Oncol Res Pract | 2016 | 0.81 |
4 | New treatment option for ovarian cancer: PARP inhibitors. | Gynecol Oncol Res Pract | 2016 | 0.80 |
5 | Emerging therapeutic targets in metastatic progression: A focus on breast cancer. | Pharmacol Ther | 2016 | 0.79 |
6 | Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. | J Transl Med | 2016 | 0.79 |
7 | Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. | Ther Adv Med Oncol | 2016 | 0.77 |
8 | Future perspectives in cancer immunotherapy. | Ann Transl Med | 2016 | 0.77 |